NCT00996008

CT 327 in the Treatment of Atopic Dermatitis

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study of the Safety and Efficacy of CT 327, Pegylated K-252, Formulated as a Cream, When Administered Twice Daily for 14 Days to Subjects With Mild-to-Moderate Atopic Dermatitis

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 15 (actual)
• Sponsor: Creabilis SA · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will look at how safe and effective, a novel agent, CT 327 cream is in treating patients with mild to moderate atopic dermatitis (AD). Patients will be treated twice daily for 14 days on specific lesions of AD and safety and symptoms of AD will be assessed throughout the treatment period.

Conditions

• Mild to Moderate Atopic Dermatitis

Interventions

Type	Name	Description
DRUG	placebo	0.5 g (w/w) placebo cream applied to each target lesion twice daily
DRUG	CT 327	0.5 g CT 327 cream will be applied to 2 target lesions twice daily 0.5 g placebo cream will be applied to remaining 2 target lesions twice daily

Timeline

• Start date: 2009-11-01
• Primary completion: 2010-10-01
• Completion: 2010-10-01
• First posted: 2009-10-16
• Last updated: 2010-10-26

Locations

5 sites across 1 country: Switzerland